

Antonia Kalushkova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9352930/publications.pdf>

Version: 2024-02-01

10
papers

348
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

788
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional loss of $\hat{\mu}$ leads to NF- \hat{B} deregulation in aggressive chronic lymphocytic leukemia. Journal of Experimental Medicine, 2015, 212, 833-843.	8.5	85
2	Polycomb Target Genes Are Silenced in Multiple Myeloma. PLoS ONE, 2010, 5, e11483.	2.5	81
3	Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget, 2016, 7, 6809-6823.	1.8	59
4	EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget, 2017, 8, 10213-10224.	1.8	47
5	A Role for the Chromatin Remodeling Factor <i>BAZ1A</i> in Neurodevelopment. Human Mutation, 2016, 37, 964-975.	2.5	29
6	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget, 2017, 8, 103731-103743.	1.8	19
7	AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochemical Pharmacology, 2014, 87, 284-291.	4.4	12
8	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma. Cell Death and Disease, 2021, 12, 167.	6.3	12
9	One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. Epigenomes, 2021, 5, 22.	1.8	3
10	MBRS-42. GMYC: A NOVEL INDUCIBLE TRANSGENIC MODEL OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i137-i137.	1.2	1